Page 5 - CCfV-Annual-Report-2013-14

Research Highlights Discovery Group From unlocking the secrets of HIGHLIGHTS viral/bacterial pathogenesis • Vaccine development for dengue, RSV and other infectious to identifying new adjuvants, disease pathogens (R. Anderson) Discovery Group researchers • Enhanced delivery of vaccines into cells using fusogenic are making exciting advances liposomes (R. Duncan) towards the development • Novel adjuvants in a mouse model of infuenza, and PCIRN’s of new, urgently required reference laboratories for infuenza antibody testing (T. Hatchette) vaccines. • Towards an oral pertussis vaccine using genetically engineered oral commensal S. gordonii (S. Lee & S. Halperin) Major fndings in 2013 included progress toward a dengue vaccine, • Surveillance of Clostridium difcile immune responses (J. further characterization of cell receptors LeBlanc) for measles and related viruses and the • Vaccine/adjuvant formulations for cancers and infectious potential targeting of these receptors diseases (M. Mansour, M. Staford) by novel anti-cancer therapeutics, identifcation of antiviral compounds • Genetic manipulation of infuenza viruses and oncogenic against hepatitis C and other viruses, herpesviruses, and the identifcation of novel drug targets at and studies into the role of lymphocyte the virus-host interface (C. McCormick) subsets in Chlamydia infection. • Engineering the vaccine strain of measles virus to create Discovery Group researchers represent recombinant multivalent vaccines. Use of measles and the felds of bacteriology, molecular related viruses for detection and oncolytic treatment of biology, virology, and immunology. We adenocarcinomas bearing the tumor marker PVRL4/Nectin-4 strive to create an environment in which (C. Richardson) close collaboration rapidly enhances • Immunoepidemiological and vaccine development studies research and development and provides for Haemophilus infuenzae (M. Ulanova) excellent training opportunities. Members of the Discovery Group • Development of viral vector-based recombinant interact with other members of the gene delivery system to stimulate mucosal immunity; Center’s Vaccine Evaluation and Health understanding the role of Th1/Th17 balance in anti- Policy & Translation Groups as well as Chlamydia immunity and development of clinical industry leaders and researchers from immunoassays and parameters for evaluation of vaccine other universities. candidates against Chlamydia (Jun Wang) Annual Report | 2013-14 3nnual Report | 2013-14 3 A